Tweet
First Trust Advisors LP lifted its position in Novo Nordisk A/S (NYSE:NVO) by 4,736.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 466,631 shares of the company's stock after purchasing an additional 456,983 shares during the quarter. First Trust Advisors LP's holdings in Novo Nordisk A/S were worth $21,521,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Loomis Sayles & Co. L P raised its stake in Novo Nordisk A/S by 6.4% during the first quarter. Loomis Sayles & Co. L P now owns 22,025,113 shares of the company's stock worth $1,084,737,000 after acquiring an additional 1,323,857 shares in the last quarter. Fisher Asset Management LLC raised its stake in Novo Nordisk A/S by 3.4% during the second quarter. Fisher Asset Management LLC now owns 13,569,671 shares of the company's stock worth $625,833,000 after acquiring an additional 440,014 shares in the last quarter. Carillon Tower Advisers Inc. acquired a new position in Novo Nordisk A/S during the first quarter worth $15,194,000. BlackRock Inc. raised its stake in Novo Nordisk A/S by 2.9% during the first quarter. BlackRock Inc. now owns 9,695,784 shares of the company's stock worth $477,518,000 after acquiring an additional 272,500 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in Novo Nordisk A/S by 14.0% during the second quarter. Wells Fargo & Company MN now owns 1,301,934 shares of the company's stock worth $60,046,000 after acquiring an additional 159,619 shares in the last quarter. Institutional investors and hedge funds own 6.75% of the company's stock. Get Novo Nordisk A/S alerts:
Novo Nordisk A/S stock opened at $47.77 on Friday. Novo Nordisk A/S has a 52-week low of $44.28 and a 52-week high of $58.37. The firm has a market cap of $114.53 billion, a price-to-earnings ratio of 20.36, a P/E/G ratio of 2.52 and a beta of 0.66.
The business also recently disclosed a special dividend, which will be paid on Tuesday, August 28th. Shareholders of record on Monday, August 20th will be paid a dividend of $0.4669 per share. The ex-dividend date of this dividend is Friday, August 17th. This represents a yield of 1.72%. Novo Nordisk A/S's dividend payout ratio is currently 38.89%.
Several research analysts have issued reports on the company. Zacks Investment Research upgraded Novo Nordisk A/S from a "sell" rating to a "hold" rating in a research note on Tuesday, July 31st. Sanford C. Bernstein upgraded Novo Nordisk A/S from a "market perform" rating to an "outperform" rating in a research note on Monday, July 2nd. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Novo Nordisk A/S presently has an average rating of "Buy" and a consensus price target of $64.00.
Novo Nordisk A/S Profile
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.
Read More: What are the Different Types of Leveraged Buyouts?
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO). Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter 